Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMG1 | Q96Q15 | 7/20 | 0.66 |
| ▸ | MTOR | P42345 | 3/20 | 0.66 |
| ▸ | BRAF | P15056 | 10/20 | 0.53 |
| ▸ | RAF1 | P04049 | 9/20 | 0.53 |
| ▸ | CDK1 | P06493 | 3/20 | 0.52 |
| ▸ | CDK2 | P24941 | 3/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL827670 | 0.82 | AURKA (0.46) | SMG1MTOR | |
| SCHEMBL827669 | 0.81 | IDH2 (0.47) | — | |
| SCHEMBL827730 | 0.79 | CLK1 (0.51) | CDK2USP2SMN1; SMN2KCNH2 | |
| SCHEMBL861455 | 0.78 | KIF11 (0.52) | SMG1MTORBRAFRAF1CDK1 | |
| SCHEMBL9217042 | 0.75 | CTSC (0.44) | — | |
| SCHEMBL827974 | 0.73 | PSEN1 (0.47) | CDK2 | |
| SCHEMBL827996 | 0.71 | PSEN1 (0.45) | CDK2 | |
| SCHEMBL827754 | 0.70 | IDH2 (0.46) | CDK2SMN1; SMN2 | |
| SCHEMBL827924 | 0.70 | IDH2 (0.44) | — | |
| SCHEMBL827573 | 0.70 | AURKA (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143419-B2 | Trisubstituted 1,2,4-triazoles | JANSSEN PHARMACEUTICA N. V. (BE) | 2012-03-27 | — | — | US | disclosed |
| US-8143419-B2 | Trisubstituted 1,2,4-triazoles | JANSSEN PHARMACEUTICA N. V. (BE) | 2012-03-27 | — | — | US | disclosed |
| US-20090253691-A1 | TRISUBSTITUTED 1,2,4-TRIAZOLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253691-A1 | TRISUBSTITUTED 1,2,4-TRIAZOLES | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253691-A1 | TRISUBSTITUTED 1,2,4-TRIAZOLES | CHRNA1, CHRNA5, CHRNA3 | SMG1 3477/4885MTOR 3153/4885BRAF 3906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.